DJS acquired by AbbVie & other autumn highlights from our innovation centres
Post created by The Oxford Trust to give insight into the science and tech businesses they support in their innovation centres: the Oxford Centre for Innovation and the Wood Centre for Innovation.
Nothing stands still in the innovation space! This autumn has been an exciting time for growth and development for companies in our Wood Centre for Innovation and Oxford Centre for Innovation. We’ve gathered some of the latest highlights to share the successes of these companies along their innovation journey.
DJS Antibodies acquired by AbbVie
A highlight of the past week has been the announcement that Wood Centre for Innovation-based DJS Antibodies has been acquired by global pharmaceutical company AbbVie for the sum of $255 million. Read the announcement from AbbVie.
DJS Antibodies’ revolutionary antibody discovery platform, HEPTAD, is breaking ground in an antibody industry that is worth over $100 billion dollars globally. It is facilitating the discovery of antibodies against proteins that have been difficult to target through drugs, like transmembrane G-protein coupled receptors (GPCRs). Their work aims to establish a pipeline of therapeutics to help patients suffering from chronic inflammatory and fibrotic diseases such as Idiopathic Pulmonary Fibrosis.
Through the acquisition, the HEPTAD platform will complement AbbVie’s current capabilities in biotherapeutics research. DJS Antibodies will continue to generate antibody therapeutics and novel insights against targets like GPCRs, enhancing their work by leveraging the established drug discovery expertise at AbbVie.
Co-founded by Dr David Lewellyn and Dr Joe Illingworth (photographed above outside the Wood Centre for Innovation), DJS Antibodies started their journey at Heyford Park Innovation Centre. They moved to the Wood Centre for Innovation in May 2021 when they successfully sourced venture capital to support them setting up their own custom labs here. When we interviewed David in June last year, we asked him about his five-year plan. He said, “We want to keep exploring great science in the pursuit of making life-saving medicines and getting them to patients. To do this we’ll have to work collaboratively with great pharma companies to accelerate our antibody drugs into clinical trials.”
Just over a year later, this plan is firmly on track. We congratulate DJS Antibodies on their success!
QuantrolOx raises €10.5m
It has also been a successful season for funding and expansion for a number of companies at our centres.
QuantrolOx, based at our Oxford Centre for Innovation, has raised €10.5m in funding from the European Innovation Council. Of this total, €2.5m is grant money available upfront, and the remaining €8m is reserved as funds to match venture capital investments from other sources, boosting appeal for investors. The funding will be used to support the launch of their product in 2023. Read the story published in Sifted.
The company has grown tremendously in their time at the Oxford Centre for Innovation, doubling their team over the last six months. From a staff of eight at the time of our first interview with Co-Founder Professor Andrew Briggs in March 2022, they have expanded to a team of 17.
CMT Research Foundation fund Samsara
Another funding success was announced this month by Samsara Therapeutics, who have secured funding in a partnership with the CMT Research Foundation. The CMT Research Foundation focuses research on treatments and cures for Charcot-Marie-Tooth (CMT) disease, a degenerative disease of various forms involving peripheral nerves, which is characterised by progressively worsening nerve degradation, numbness and muscle weakness.
CMT1A is a form of CMT currently without any therapeutic treatment options. Samsara Therapeutics hope to fill this gap, through their work on therapeutics to restore autophagy – the process by which cells recycle damaged or dysfunctional components. They have demonstrated that with novel autophagy enhancers they can rescue CMT1A nerve degeneration in mice, showing exciting potential for CMT1A therapeutics with further exploration.
This is the largest investment the CMT Research Foundation has made to date, and the dedicated project will facilitate further optimisation of pipeline autophagy compounds, scale up manufacturing of the candidate, and clinical trials that may lead to a treatment option for CMT patients. Read more about the project here.
Human Centric appoints all-female lab team
One of our newer clients joining the Wood Centre for Innovation this year, Human Centric Drug Discovery, is excited to now have their full lab team in place. An all-female, multinational team will be using their expertise to help find a new generation of drugs to treat brain disorders, such as migraines and Parkinson’s Disease. HCCD’s approach to drug discovery draws from multiple sources of data – data from laboratory cell culture, data from genetics, and data from real-world health system databases. This multi-faceted approach is refining the pipeline to successful therapeutics. Read more about their work in our interview with CEO, James Peach, earlier this year.
Autumn news from companies in our innovation centres
There have been many exciting developments for companies in our two innovation centres, the Wood Centre for Innovation and the Oxford Centre for Innovation In case you’ve missed any of the good news, we’ve put together a collection of highlights from the past few months. New companies in our centres We’re pleased to have […]
Five minutes with Jonathan Musgrove, CEO of Oxford Sigma
We are pleased to welcome fusion materials technology start-up Oxford Sigma to our Oxford Centre for Innovation (read the news story here). We sat down with co-founder and CEO Jonathan Musgrove to discover more about their work and vision for the future of the company.
Five minutes with NavLive co-founders Dr David Wisth and Prof Maurice Fallon
University of Oxford spinout NavLive has recently joined the community of inspiring deep-tech start-ups at our Oxford Centre for Innovation. With its advanced 3D mapping technology, it aims to create new norms in the complex management of building sites, bringing economic benefits to the building and construction sector. We spoke to its co-founders, […]